Vertex Pharma (VRTX) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY26 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. INTC
2. AMZN
3. COIN
4. RDDT
5. PINS
6. FSLR
7. DASH
8. SYK
9. MA
10. FND

Go back to Vertex Pharma (VRTX) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY26 Revenue Guidance

Vertex Reports Second Quarter 2026 Financial Results

August 3, 2026 4:01 PM EDT

Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025

Raising full-year revenue guidance to $13.1 billion to $13.2 billion

Continued progress across research and development pipeline; povetacicept PDUFA date November 30th

Entered into agreement to acquire Crinetics Pharmaceuticals, with closing anticipated in the third quarter of 2026

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance.

Vertex delivered excellent second quarter results,... More